Did you perhaps just wanna tell us what your concerns are in using these tools?

Actually, when we prepare this, we read, read about a, a lot of the works of Andy here.

So [chuckles] yeah, I, I think this was made on purpose, but okay.

Yes.

I think the, the main concern we, that we have is that it's the same as Andy mentioned already, that we have new s- new signs that are very specific, but the sensitivity is still the same, right? And it, it's always the same with, with MS.

We don't have a gold standard to compare our criteria against with.

And, and I think that's one of the main issues that we have with, with particularly with the new imaging markers, the PRLs and the central venous sign.

Are we-- is there a real risk here that we're going to over-diagnose patients as-- uh, with the increased sensitivity and the expansion?